Clinical-stage drug discovery, development and manufacturing company Sutro Biopharma Inc (NASDAQ: STRO) disclosed on Wednesday that James P Panek has been appointed to its board of directors.
With over 40 years of experience in the biotech and pharmaceutical industry, Panek has worked as an independent consultant since 2011.
Previously, Panek held leadership positions at VaxGen, from 2002 to 2010. While at VaxGen, Panek served as co-ceo and chairman of its international joint venture, Celltrion. He was appointed chief executive officer at VaxGen in 2007.
Panek also held several leadership positions during an 18-year tenure at Genentech.
Sutro Biopharma is focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics. To date, Sutro has designed cytokine-based immuno-oncology therapies, ADCs, vaccines and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer